Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Roflumilast Altana Pharma.

Peter Reid1

  • 1Western General Hospital, Edinburgh, UK. Peter.Reid@luht.scot.nhs.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|September 5, 2002
PubMed
Summary
This summary is machine-generated.

Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, is being developed for treating asthma and chronic obstructive pulmonary disease. This targeted therapy aims to address inflammatory pathways involved in these respiratory conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early life treatment with Lacticaseibacillus rhamnosus strains drives reduced enteric methane emissions in dairy heifers.

Journal of animal science and biotechnology·2026
Same author

Milk fatty acids and rumen composition as proxy measures of enteric methane.

Journal of dairy science·2025
Same author

Effect of buffer pH on methane production and fermentation characteristics of three forages tested in vitro.

Journal of the science of food and agriculture·2024
Same author

The effect of fentanyl coadministration on sneezing during nasal local anesthetic injection for plastic surgery under propofol-based intravenous sedation: A retrospective case-controlled study.

Journal of opioid management·2023
Same author

<i>Methanobrevibacter boviskoreani</i> JH1<sup>T</sup> growth on alcohols allows development of a high throughput bioassay to detect methanogen inhibition.

Current research in microbial sciences·2023
Same author

Substituting ryegrass-based pasture with graded levels of forage rape in the diet of lambs decreases methane emissions and increases propionate, succinate, and primary alcohols in the rumen.

Journal of animal science·2022
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Asthma and chronic obstructive pulmonary disease (COPD) are significant respiratory diseases characterized by inflammation.
  • Phosphodiesterase 4 (PDE4) is a key enzyme involved in inflammatory processes within the airways.

Purpose of the Study:

  • To investigate Roflumilast, a specific PDE4 inhibitor, as a potential therapeutic agent.
  • To explore the efficacy of Roflumilast in the context of asthma and COPD treatment.

Main Methods:

  • Development of Roflumilast by Altana Pharma (formerly Byk Gulden).
  • Focus on specific inhibition of the PDE4 enzyme.

Main Results:

  • Roflumilast demonstrates potential as a treatment for respiratory inflammatory conditions.

Related Experiment Videos

  • The drug targets the PDE4 enzyme pathway.

    • Conclusions:

    • Roflumilast represents a promising therapeutic candidate for asthma and COPD.
    • Targeting PDE4 offers a specific approach to managing these diseases.